Bioventus Inc.
NASDAQ · us_market
No AI summary generated yet for this ticker.
Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides neXus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; BoneScalpel Access, for bone removal with visualization; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company's restorative therapies include minimally invasive fracture treatments and rehabilitation products. Its products also include Exogen, an ultrasound bone stimulation system. The company sells its products to healthcare institutions, physicians, patients, distributors and dealers. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina.
Bioventus (BVS) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
On April 16, 2026, the U.S. Food and Drug Administration ("FDA") issued a final order reclassifying non-invasive bone growth stimulators, including the Company's Exogen® Ultrasound Bone Healing System, from Class
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Here is how Bioventus (BVS) and Allarity Therapeutics, Inc. (ALLR) have performed compared to their sector so far this year.
Here is how Bioventus (BVS) and Allarity Therapeutics, Inc. (ALLR) have performed compared to their sector so far this year.
Consumer confidence is breaking down in a way investors have not seen in years. The University of Michigan Consumer Sentiment Index landed at 53.3 in March 2026, sitting below the 60 recessionary threshold, and the latest Surveys of Consumers reading dropped further to 49.8 in April 2026, a 6.6% month-over-month decline matching the trough from ... Consumer Sentiment Just Crashed Below the Recession Threshold. These 3 Defensive Stocks Under $25 Are Built for What Comes Next
Consumer confidence is breaking down in a way investors have not seen in years. The University of Michigan Consumer Sentiment Index landed at 53.3 in March 2026, sitting below the 60 recessionary threshold, and the latest Surveys of Consumers reading dropped further to 49.8 in April 2026, a 6.6% month-over-month decline matching the trough from ... Consumer Sentiment Just Crashed Below the Recession Threshold. These 3 Defensive Stocks Under $25 Are Built for What Comes Next
Investors were underwhelmed by the solid earnings posted by Bioventus Inc. ( NASDAQ:BVS ) recently. We did some digging...
Investors were underwhelmed by the solid earnings posted by Bioventus Inc. ( NASDAQ:BVS ) recently. We did some digging...
The consensus price target hints at a 39% upside potential for Bioventus (BVS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
The consensus price target hints at a 39% upside potential for Bioventus (BVS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Moby summary of Bioventus Inc.'s Q1 2026 earnings call
Moby summary of Bioventus Inc.'s Q1 2026 earnings call
It is my pleasure to welcome you to the Bioventus 2026 First Quarter Earnings Conference Call. With me this morning are Rob Claypoole, President and CEO; and Mark Singleton, Senior Vice President and CFO.
It is my pleasure to welcome you to the Bioventus 2026 First Quarter Earnings Conference Call. With me this morning are Rob Claypoole, President and CEO; and Mark Singleton, Senior Vice President and CFO.
Bioventus (NASDAQ:BVS) reported first-quarter 2026 results that management said put the company “off to a strong start” as it increased investment in several growth drivers while still expanding profitability and cash generation. On the call, the company also raised guidance for adjusted earnings pe
Bioventus (NASDAQ:BVS) reported first-quarter 2026 results that management said put the company “off to a strong start” as it increased investment in several growth drivers while still expanding profitability and cash generation. On the call, the company also raised guidance for adjusted earnings pe
Bioventus Inc. (BVS) Q1 2026 Earnings Call May 6, 2026 8:30 AM EDTCompany ParticipantsDavid Crawford - Vice President of Investor Relations &...
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| StateStreet | passive | 988.4K | $9.02M | 0.00% | Added+10.9% | 2026-03-31 |
| RenTech | quant | 489.5K | $4.47M | 0.01% | Trimmed-20.4% | 2026-03-31 |
| FidelityFMR | fundamental | 396.2K | $3.62M | 0.00% | Added+8.1% | 2026-03-31 |
| DEShaw | quant | 310.6K | $2.84M | 0.00% | Trimmed-13.3% | 2026-03-31 |
| TwoSigma | quant | 259.1K | $2.37M | 0.00% | Trimmed-3.6% | 2026-03-31 |
| Wellington | fundamental | 154.1K | $1.41M | 0.00% | New | 2026-03-31 |
| TRowePrice | fundamental | 36.8K | $337 | 0.00% | Added+49.3% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-04upcoming | 0.22 | — | — |
| 2026-05-06 | 0.07 | 0.15 | +120.59% |
| 2026-03-05 | 0.22 | 0.24 | +10.77% |
| 2025-11-04 | 0.12 | 0.15 | +30.43% |
| 2025-08-06 | 0.20 | 0.21 | +6.78% |
| 2025-05-06 | -0.12 | -0.04 | +68.00% |
| 2025-03-11 | 0.08 | 0.15 | +76.49% |
| 2024-11-05 | 0.02 | 0.06 | +296.83% |
| 2024-08-06 | 0.07 | 0.19 | +191.14% |
| 2024-05-07 | -0.07 | 0.07 | +206.89% |
| 2024-03-12 | 0.02 | 0.07 | +225.58% |
| 2023-11-07 | -0.02 | 0.05 | +340.15% |
| 2023-08-08 | — | 0.14 | +3755.35% |
| 2023-05-16 | -0.16 | -0.26 | -59.19% |
| 2023-03-31 | 0.05 | -0.06 | -226.21% |
| 2022-11-08 | 0.12 | 0.08 | -34.54% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| BVS | -15.83% | -2.63% | +14.38% | +31.33% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | -18.80% | +2.01% | +17.82% | +18.64% |